Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
Location: Netherlands, South Holland, Leiden
Employees: 1-10
Total raised: $85.32M
Investors 4
| Date | Name | Website |
| 22.04.2021 | M Ventures | m-ventures... |
| 11.05.2023 | MRL Ventur... | mrlv.com |
| 29.04.2021 | Taiho Vent... | taihoventu... |
| - | Bioqube Ve... | bioqubeven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.05.2023 | - | $30.5M | - |
| 03.05.2023 | Seed | $30.7M | M Ventures |
| 22.04.2021 | Seed | $24.12M | - |
Mentions in press and media 11
| Date | Title | Description |
| 17.10.2024 | Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US | Leiden, The Netherlands – October 9, 2024 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, today announced the appointment of Edward Holson, Ph.D., as Chief Scientific Officer (CSO). ... |
| 05.05.2023 | Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic | Leiden, The Netherlands, and Heidelberg, Germany, May 2, 2023 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, announced today an EUR 8.5 million seed round extension, adding MR... |
| 03.05.2023 | Dutch-based Anavo Therapeutics secures €8.5M to systematically drug phosphatases: Know more | Leiden-based Anavo Therapeutics, a company that claims to be the first to systematically drug phosphatases – a rich target space previously considered undruggable for decades, announced that it has raised €8.5M in a Seed extension round of ... |
| 02.05.2023 | Anavo Therapeutics Raises €8.5M; Extends Seed Round to €28M | Anavo Therapeutics, a Leiden, Netherlands- and Heidelberg, Germany-based human phosphatase biology company, raised €8.5M in an extension of its Seed round, which brought the total amount to €28M. Backers included MRL Ventures Fund as a new ... |
| 22.04.2021 | Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators | Leiden, The Netherlands, April 22, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx. $24 million) seed financing. Anavo’s missio... |
| 22.04.2021 | Anavo Therapeutics : Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators | Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx. $24 million) seed financing. Anavo’s mission is to pioneer systematic drug discovery ... |
| 19.10.2018 | Anavo Technologies Announces $3.6 Million Investment by Blue Hill Group | Anavo Technologies, an intellectual property holding company that identifies and capitalizes on new technologies, announced today a $3.6 million investment in its first spinoff, Next Century Spirits, led by Blue Hill Group, a private equity... |
| - | Anavo Therapeutics | “UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.” |
| - | Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster | Leiden, The Netherlands, and Heidelberg, Germany, August 16, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced that the company has partnered with BioLabs Gl... |
| - | Anavo Therapeutics: €28 Million Seed Round Secured For Unlocking The Potential of Human Phosphatase Biology | Anavo Therapeutics – a global leader in unlocking the full therapeutic potential of human phosphatase biology – announced recently an €8.5 million seed round extension, adding MRL Ventures Fund as a new investor. And all existing investors,... |
Show more